UK Industry Rebates Could Make NICE Cost-Effectiveness Assessments Unnecessary
Executive Summary
Roche has praised the flexibility of the UK’s Cancer Drugs Fund, but says NICE cost-effectiveness analysis would be unnecessary if industry rebates fed into a UK drugs budget.
You may also be interested in...
Roche’s Gazyvaro Is Fifth Drug To Enter UK Cancer Drugs Fund
Roche’s Gazyvaro is the fifth drug to be recommended by UK HTA body NICE for use on an interim fund that gives manufacturers more time to gather evidence to prove their drugs are cost-effective and win long-term funding on the National Health Service.
NICE Turns Attention To Roche's Perjeta After Finally Passing Kadcyla For Breast Cancer
After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA body NICE will now decide how to respond to the Swiss group's proffered patient access scheme for Perjeta.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.